Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimicotinib in Tenosynovial Giant Cell Tumor
NCT05804045Phase 3Active, not recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Apr 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of pimicotinib in tenosynovial giant cell tumor (TGCT), sponsored by Abbisko Therapeutics. Started Apr 2023; status: active, not recruiting.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT05804045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804045.